Why the study?
Does ACE-I and/or ARB therapy improve renal and cardiovascular outcomes in adults with proteinuria and microalbuminuria?
Population
Adults with microalbuminuria (especially diabetics) and proteinuria
Design
Review
Authors
Loading...
Supports ACE-I/ARB for proteinuria and CV protection; leaves open need for updated RCTs before changing practice.
Does ACE-I and/or ARB therapy improve renal and cardiovascular outcomes in adults with proteinuria and microalbuminuria?
This review emphasizes the importance of screening for microalbuminuria and proteinuria in adults, and highlights ACE-I/ARB therapy for renal and cardiovascular protection.
K.K. Venkat (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: